Stephen B. Baylin
Founder of cancer epigenetics, showing that abnormal DNA methylation silences tumour-suppressor genes and can be reversed by drugs.
Established promoter hypermethylation as a mechanism of gene silencing in cancer and led early trials of low-dose azacitidine and HDAC inhibitors in solid tumours.
| Title | Journal | Year |
|---|---|---|
| A decade of exploring the cancer epigenome — biological and translational implications | Nature Reviews Cancer | 2011 |
Pages like this
not linked directly; found by shared links- InstitutionUSC Norris Comprehensive Cancer Center
Shares Azacitidine, DNA methylation profiling, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
- PersonWilliam G. Nelson
Shares Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- TermHypomethylating agents (azacitidine, decitabine)
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
- IdeaSwitch off an undruggable oncogene permanently with epigenetic editing
Shares DNA methylation profiling, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- InstitutionNational University Hospital / National University Cancer Institute, Singapore
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia, Non-small-cell lung cancer.
- IdeaUnmask hidden antigens with a short epigenetic course before immunotherapy
Shares Azacitidine, DNA methylation profiling, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Non-small-cell lung cancer.
- TrialAGILE
Shares Azacitidine, Acute myeloid leukaemia.
- PersonChristopher R. Vakoc
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.